Pricing Availability   Qty
Description: Potent competitive NMDA antagonist
Alternative Names: Midafotel,SDZ EAA 494
Chemical Name: D-4-[(2E)-3-Phosphono-2-propenyl]-2-piperazinecarboxylic acid
Citations (2)
Literature (5)

Biological Activity for D-CPP-ene

D-CPP-ene is a potent and competitive NMDA antagonist (Ki = 40 nM). Centrally active following systemic administration.

Technical Data for D-CPP-ene

M. Wt 250.19
Formula C8H15N2O5P
Storage Desiccate at RT
CAS Number 117414-74-1
PubChem ID 6435801
Smiles O=P(/C=C/CN1C[C@H]([C@](O)=O)NCC1)(O)O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for D-CPP-ene

Solvent Max Conc. mg/mL Max Conc. mM
water 25 100

Preparing Stock Solutions for D-CPP-ene

The following data is based on the product molecular weight 250.19. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 4 mL 19.98 mL 39.97 mL
5 mM 0.8 mL 4 mL 7.99 mL
10 mM 0.4 mL 2 mL 4 mL
50 mM 0.08 mL 0.4 mL 0.8 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Product Datasheets for D-CPP-ene

Certificate of Analysis / Product Datasheet
Select another batch:

References for D-CPP-ene

References are publications that support the biological activity of the product.

Lowe et al (1990) D-CPP-ene (SDZ EAA 494), a potent and competitive N-MthD.-aspartate (NMDA) antagonist: effect on spontaneous activity and NMDA-induced depolarizations in the rat neocortical slice preparation, compared with other CPP derivatives and MK-801. Neurosci.Lett. 113 315 PMID: 2166255

Potschka et al (1999) Effects of the NMDA receptor antagonist D-CPPene on extracellular levels of DA and DA and serotonin metabolites in striatum of kindled and non-kindled rats. Eur.J.Pharmacol. 374 175 PMID: 10422758

Aebischer et al (1989) Synthesis and NMDA antagonistic properties of the enantiomers of 4-(3-phosphonopropyl)piperazine-2-carboxylic acid (CPP) and of the unsaturated analogue (E)-4-(3-phosphono-2-enyl)piperazine-2-carboxylic acid (CPP-ene). Helv.Chim.Acta 72 1043

If you know of a relevant reference for D-CPP-ene, please let us know.

View Related Products by Target

View Related Products by Product Action

View all NMDA Receptor Antagonists

Keywords: D-CPP-ene, D-CPP-ene supplier, Potent, competitive, NMDA, antagonists, Glutamate, Receptors, N-Methyl-D-Aspartate, iGlur, Ionotropic, SDZEAA494, Midafotel, SDZ, EAA, 494, 1265, Tocris Bioscience

2 Citations for D-CPP-ene

Citations are publications that use Tocris products. Selected citations for D-CPP-ene include:

Cheng et al (2018) ATM and ATR play complementary roles in the behavior of excitatory and inhibitory vesicle populations. Proc Natl Acad Sci U S A 115 E292 PMID: 29279380

Campos and Ritter (2015) NMDA-type glutamate receptors participate in reduction of food intake following hindbrain melanocortin receptor activation. Oncogene 308 R1 PMID: 25394828

Do you know of a great paper that uses D-CPP-ene from Tocris? Please let us know.

Reviews for D-CPP-ene

There are currently no reviews for this product. Be the first to review D-CPP-ene and earn rewards!

Have you used D-CPP-ene?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Huntington's Disease Research Product Guide

Huntington's Disease Research Product Guide

This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:

  • Somatic Instability
  • Proteolysis and Inclusion Bodies
  • Transcriptional Dysregulation
  • Mitochondrial Dysfunction
  • Nuclear-Cytoplasmic Transport Interference
  • Excitotoxicity
  • Stem Cells
Alzheimer's Disease Poster

Alzheimer's Disease Poster

Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Huntington's Disease Poster

Huntington's Disease Poster

Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.